Are Stem Cell Treatments Legal in Mexico? A COFEPRIS Compliance Guide

What is COFEPRIS?

COFEPRIS — the Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority. It is the Mexican equivalent of the FDA in the United States: a regulatory agency operating under the Secretaría de Salud (Ministry of Health) that controls medical devices, drugs, biologics, food safety, advertising of health services, and the licensing of medical establishments.

Any clinic that offers regenerative medicine in Mexico — including stem cell therapy, exosome therapy, peptide protocols, or PRP — is required to operate under at least two COFEPRIS authorizations: an Aviso de Funcionamiento (operating notice) tied to the physical establishment, and an Aviso de Publicidad (advertising notice) tied to the way the services are described to the public. Sourcing of biological products is regulated through additional COFEPRIS routes for tissue banks, blood banks, and the laboratories that manufacture cellular preparations.

How COFEPRIS regulates stem cell therapy

Stem cell therapy in Mexico sits at the intersection of several regulatory frameworks. COFEPRIS authorizes the establishment (Aviso de Funcionamiento), supervises the advertising claims a clinic can legally make (Aviso de Publicidad), regulates the laboratories that process the cells (Disposición de Células Troncales), and — through the General Health Law and its regulations on medical care — defines who may legally administer a regenerative protocol.

In practice this means three things for the patient. First, the cells themselves must come from a COFEPRIS-registered tissue or processing facility, with documented donor screening and chain of custody. Second, the clinic that infuses or injects the cells must have an active health notice on file and a designated Responsable Sanitario (health officer) with a verifiable cédula profesional. Third, the physician who performs the procedure must hold an active cédula profesional issued by the Secretaría de Educación Pública (SEP) — Mexico's federal professional licensing authority.

Mexico does not yet have a single, monolithic regulation that covers every regenerative therapy end-to-end the way the FDA's IND framework does in the United States. What it does have is a layered system of NOMs (Normas Oficiales Mexicanas), COFEPRIS rulings, and General Health Law provisions that together establish the floor a legitimate clinic must operate above. The clinics that take patient safety seriously document each layer publicly, on a regulatory page like ours, instead of asking patients to trust an unverifiable claim.

FDA vs COFEPRIS — what is the actual difference?

The most common question from US patients is some version of "if the FDA hasn't approved this therapy, how can it be legal in Mexico?" The honest answer is that the FDA and COFEPRIS use different categorization frameworks for cellular products — neither agency is more or less strict in the absolute sense, but they draw the line in different places.

Three differences that matter to patients

• Investigational vs authorized practice. Most allogeneic stem cell products in the United States sit inside the FDA's IND (Investigational New Drug) pathway, which means they can only be administered inside a registered clinical trial. In Mexico, COFEPRIS allows physicians to use mesenchymal stem cell preparations from authorized laboratories as part of medical practice, provided the clinic, the lab, and the physician all hold the correct licenses.
• Where the regulation lives. FDA regulation centers on the product (the biologic itself goes through approval). COFEPRIS regulation centers on the establishment and the supply chain: the clinic, the lab, the physician, and the advertising material each carry an authorization, and patients can verify each one independently.
• Advertising and patient claims. COFEPRIS requires an explicit Aviso de Publicidad before a clinic can publish marketing claims about a regenerative therapy. There is no equivalent FDA pre-clearance for clinic marketing in the United States — which is why so many US patients encounter aggressive claims online from clinics that would not be allowed to advertise the same way in Mexico.

Patients sometimes assume "FDA-approved" is the global gold standard. In a country where the FDA has no jurisdiction, the question that actually protects you is whether the Mexican clinic in front of you is operating inside the rules its own regulator has written — and whether you can verify it.

How to verify a clinic's COFEPRIS authorization

Every COFEPRIS authorization is a public record. Before paying a deposit for stem cell therapy in Mexico, take twenty minutes and confirm the following five things with the clinic in writing:

1. Ask for the Aviso de Funcionamiento number. This is the operating notice for the physical establishment. It is a long alphanumeric string (ours is 2323025036X00098). The clinic should publish it on a dedicated regulatory page, not just say the words "COFEPRIS regulated" in a paragraph somewhere.
2. Ask for the Aviso de Publicidad number. This is the advertising notice that authorizes the clinic to make marketing claims about regenerative therapy. A clinic that lacks this notice but publishes treatment claims is, strictly speaking, advertising in violation of COFEPRIS rules — which is itself a warning sign.
3. Ask who the Responsable Sanitario is. Every Mexican medical establishment must designate a health officer — a licensed physician who is legally accountable for the clinic's compliance. The clinic should be willing to name this person and provide their cédula profesional.
4. Verify the treating physician's cédula profesional. Take the cédula number for the physician who would actually administer the protocol and check it yourself at cedulaprofesional.sep.gob.mx. The SEP registry is free, public, and authoritative. If the physician cannot or will not provide a cédula, walk away.
5. Ask where the cells come from. The clinic should be able to name the COFEPRIS-registered laboratory that supplies the stem cell preparations and describe its donor screening protocol. Vague answers ("we have our own lab", "the cells are imported") without a registered facility name are a flag.

The official COFEPRIS portal is available at gob.mx/cofepris and the SEP National Registry of Professionals at cedulaprofesional.sep.gob.mx.

Regeneris Therapy COFEPRIS credentials

We publish our own regulatory footprint in full so you can verify everything before your first call.

Our public regulatory record

• Aviso de Funcionamiento (Operating Notice)

  2323025036X00098

• Aviso de Publicidad (Advertising Notice)

  2323022002A00053

• Legal name

  Regeneris Therapy

• Health Officer (Responsable Sanitario)

  Dr. Misael González Montenegro · Cédula 13226492

• Medical Director

  Dra. Marian Tufano · Cédula 12353680

• Establishment

  Av. Tulúm SM 11 MZ 1 Lote 1 Local 207, Cancún, Quintana Roo 77504

See the full regulatory page · Meet the physicians with verifiable cédulas

Donor screening and lab accreditation requirements

The donor screening protocol for allogeneic mesenchymal stem cells (MSCs) is one of the strongest safety filters in regenerative medicine — and one of the easiest places for an under-regulated clinic to cut corners. A legitimate Mexican supply chain mirrors the international standards published by organizations like ISCT and AABB, and is documented at the laboratory that processes the cells, not at the clinic that infuses them.

A compliant donor pipeline involves explicit informed consent from the donor, infectious disease screening (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum, with additional regional tests depending on the donor's geography), genetic and hereditary disease screening, and a documented chain of custody from collection through cryopreservation and shipment. The receiving clinic should be able to produce a Certificate of Analysis (CoA) for each lot before infusion, listing the donor screening results, cell viability, surface marker characterization (CD90+/CD73+/CD105+ for MSCs), and absence of contamination.

Lab accreditation in Mexico is administered by COFEPRIS through the Comisión de Autorización Sanitaria, with additional sector standards under NOM-253-SSA1-2012 for the disposition of human blood and its components. Laboratories that supply cellular preparations to clinics must hold an active operating license and are subject to periodic inspection. International accreditations — ISO 9001 for quality management, ISO 13485 for medical devices, NB-MED for biologics — are common in the better facilities and worth asking about.

Red flags to avoid in international stem cell clinics

The international medical tourism market for stem cell therapy attracts both legitimate clinics and a long tail of underqualified operators. The pattern is consistent enough that a short checklist filters out most of the worst:

• No COFEPRIS numbers anywhere on the website. A clinic that calls itself "COFEPRIS regulated" but does not publish its actual Aviso de Funcionamiento number is either negligent about transparency or hoping you will not ask. The number is required and is not confidential.
• Refuses to name the supplying laboratory. If the clinic cannot or will not name the COFEPRIS-registered lab that processes the cells, you are being asked to trust a black box. Reputable suppliers in Mexico are happy to be named.
• Treatment plan with no physician evaluation. A protocol that is quoted by a sales representative over WhatsApp without a prior medical consultation with a licensed physician is, by definition, outside the standard of care. Walk away.
• Guaranteed cures or 'always works' language. Mesenchymal stem cell therapy is supportive and evolving. No legitimate clinic guarantees outcomes — and the COFEPRIS advertising rules prohibit that kind of claim. Marketing that promises certainty is non-compliant on its face.
• Cell counts that drift wildly between quotes. A serious protocol specifies the cell type, the cell count, the route of administration, and the source laboratory in writing. If the numbers change from quote to quote, the documentation is not real.
• No written informed consent before payment. Mexican law (NOM-004-SSA3-2012) requires written informed consent for any relevant medical procedure. A clinic that collects a deposit before any consent paperwork is non-compliant before you have even arrived.

Frequently asked questions

Information for educational purposes only. Consult our medical team for individualized advice. Outcomes vary by patient and depend on prior medical evaluation.